<DOC>
	<DOC>NCT01352663</DOC>
	<brief_summary>This is an open label, randomized, parallel group comparison of the immunogenicity safety of Wockhardt's Recombinant Insulin Analogue with the innovator's Glargine in Type 1 diabetics patients.</brief_summary>
	<brief_title>Immunogenicity Safety Study of Wockhardt's Recombinant Insulin Analogue in Type 1 Diabetic Patients</brief_title>
	<detailed_description>To evaluate and compare the Immunogenicity Safety of Wockhardt's Recombinant Insulin Analogue with innovator's Glargine.</detailed_description>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>1. Patients who have been prediagnosed as cases of type1 diabetes for a period not less than 1 year 2. Male or Female Patients &gt;= 18 and =&lt; 55 years of age. 3. Patients with BMI of 18.0 to 30.0 kg/m2 4. Patients who are cooperative, reliable, and agree to have regular injections of insulin and are willing to comply with protocol procedures. 1. A Patient who is pregnant or is currently breastfeeding. 2. A Patient with history of severe hypoglycemia within the past year 3. A Patient who is an employee of the Investigator, or a patient who has a direct involvement with the trial or other trials under the direction of the Investigator. 4. Patients who are Hepatitis B or C positive on testing or have positive medical history of HIV at screening. 5. Patients unlikely to comply with the study protocol e.g. unable to return periodically for subsequent visits.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Type I Diabetes</keyword>
	<keyword>Wockhardt</keyword>
	<keyword>Insulin Analogue</keyword>
</DOC>